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S U M M A R Y
Objectives: Controlled human infection, the intentional infection of healthy volunteers, allows disease
pathogenesis to be studied and vaccines and therapeutic interventions to be evaluated in a controlled
setting. A systematic review of randomized controlled trials of countermeasures for inﬂuenza that used
the experimental human infection platform was performed. The primary objective was to document the
scope of trials performed to date and the main efﬁcacy outcome in the trials. The secondary objective was
to assess safety and identify serious adverse events.
Methods: The PubMed database was searched for randomized controlled inﬂuenza human challenge
studies with predetermined search terms. Review papers, papers without outcomes, community-
acquired infections, duplicated data, pathogenesis studies, and observational studies were excluded.
Results: Twenty-six randomized controlled trials published between 1947 and 2014 ﬁt the study
inclusion criteria. Two-thirds of these trials investigated antivirals and one-third investigated inﬂuenza
vaccines. Among 2462 subjects inoculated with inﬂuenza virus, the incidence of serious adverse events
was low (0.04%). These challenge studies helped to down-select three antivirals and one vaccine that
were subsequently approved by the US Food and Drug Administration (FDA).
Conclusions: Controlled human infection studies are an important research tool in assessing promising
inﬂuenza vaccines and antivirals. These studies are performed quickly and are cost-effective and safe,
with a low incidence of serious adverse events.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Controlled human infection (CHI) studies, in which volunteers
are intentionally infected with a pathogen, have historically been
used to advance understanding of the pathogenesis, prevention,
and treatment of a variety of infectious diseases.1 CHI, also called
human challenge studies, go back several centuries. Scientiﬁc
status was achieved in 1776 when Edward Jenner demonstrated
protection against smallpox by deliberately infecting a young boy
ﬁrst with cowpox virus and then smallpox.2 The advantages of CHI
approaches are that baseline status, host factors, timing, and the
inoculation dose of infection are known and the pathogen is well-
characterized. This allows for detailed studies on pathogenesis,* Corresponding author.
E-mail address: sbalasingam@ntu.edu.sg (S. Balasingam).
http://dx.doi.org/10.1016/j.ijid.2016.05.013
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).incubation time, time-course of disease progression, attack rates,
and correlates of protection, in addition to efﬁcacy studies of
therapeutic and prophylactic interventions. Furthermore, en-
hanced by carefully timed sample taking, a whole range of basic
science questions can be addressed.3
Indeed, CHI studies have rapidly become a core platform for
performing proof-of-concept (POC) studies of potential vaccines
and antivirals. In comparison to phase 2 and 3 trials, trials using the
CHI platform require a smaller number of subjects, can be
conducted in a shorter time frame, provide an early signal of
efﬁcacy that may allow for further product optimization, and can
be a gatekeeper to discontinue or justify further investment.
Challenge studies can also be done independently of seasons or
outbreaks. This is especially relevant for diseases such as inﬂuenza,
where variations in seasonal attack rates by geography and age can
lead to delays in the commencement of trials, or there is a risk of
not achieving recruitment of the calculated sample size when trialsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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effective research design to down-select potential vaccine or drug
candidates, enabling only the most promising agents to move
forward to a larger trial and thereby reducing the duration of
the process from drug/vaccine development to introduction to the
market.
CHI POC studies evaluating potential vaccines and antivirals
follow extensive pre-clinical and pre-clinical animal testing.
Currently, there are three animal models used for inﬂuenza
research, namely the mouse, guinea pig, and ferret models;
however, all three have limitations. Of the three models, the ferret
model exhibits clinical symptoms that most closely mimic human
symptoms of inﬂuenza, such as fever, sneezing, nasal discharge,
lethargy, and anorexia. However, ferrets are usually low in supply
and expensive; there is also a lack of ferret-speciﬁc immunological
reagents available, which limits the immunological analysis
following challenge.4 Mice, when challenged with inﬂuenza,
exhibit symptoms such as anorexia, hunching, laboured breathing,
and lack of grooming, whilst the guinea pig does not display any
clinical symptoms of infection. Both of these models are readily
available, are easy to handle, and are relatively inexpensive
compared to the ferret model. However, unlike the other two
animal models, the mouse model requires a mouse-adapted strain
of inﬂuenza and exhibits a lower attack rate of respiratory infection
following challenge. As for ferrets, there is a lack of guinea pig-
speciﬁc immunological reagents available, which again make
assessment of the immune response difﬁcult.5Whilst these animal
models are an important step in evaluating potential vaccines and
antivirals for inﬂuenza, the limitations of each make CHI studies an
invaluable and integral step of the pathway.
Because of the global spread of inﬂuenza affecting billions of
people over the past decades, inﬂuenza viruses have been a
frequently used pathogen for CHI. Although human inﬂuenza virus
was not isolated until 1933, deliberate exposure of volunteers to
respiratory secretions and other biological ﬂuids was undertaken
during the 1918 pandemic to attempt to determine the causative
pathogen. Human challenge studies with respiratory viruses such
as those causing common colds and inﬂuenza were frequently
performed in the latter part of the 20th century. The earliest
challenge study where volunteers were successfully inoculated
with inﬂuenza was performed in Russia by Smorodintseff et al. in
1937 using aerosolized inﬂuenza H1N1 strains.6 This challenge
study demonstrated that the volunteers who had a high level of
baseline neutralizing antibody were protected from infection.7
Following the study of Smorodintseff et al., advances were made in
developing inﬂuenza vaccines. The human challenge platform was
used in three studies to determine efﬁcacy of the ﬁrst generation of
inﬂuenza vaccines, against both type A and type B strains,
produced by chemically inactivating virus-infected allantoic ﬂuid
using formalin.8–10 All three studies showed that vaccination
conferred some protection to the vaccinees against the inﬂuenza
challenge virus. These studies led to the challenge platform being
used to test the efﬁcacy of the next generation of inﬂuenza
vaccines, i.e., the live attenuated vaccines.11–14
The ﬁrst pivotal study that showed the usefulness of the
challenge platform in evaluating antiviral efﬁcacy against inﬂuen-
za was performed by Jackson et al. and was published in 1963.15
Challenge studies have subsequently been performed successfully
at many institutions/centres, particularly in the USA and UK.
Randomized controlled trials (RCTs) are considered the gold
standard for clinical trials and are used as the basis for many CHI
studies to evaluate prophylactic and therapeutic measures against
a range of organisms. To this end, a systematic review of published
human challenge studies that employed inﬂuenza virus challenge
in RCTs testing either vaccines or antivirals was conducted. An
overview of all such trials that were conducted between 1947 and2014, published in the English language literature, is provided. The
objectives were to determine the extent to which CHI-based
approaches have been used to study antivirals and vaccines for
inﬂuenza, the main ﬁndings of such studies, the safety of CHI with
inﬂuenza virus, and the performance characteristics of the various
models used.
2. Methods
The United States National Library of Medicine and the National
Institutes of Health Medical Database (PubMed) were searched
from 1947 until December 2014 using the following search terms:
‘‘inﬂuenza’’ (all ﬁelds) AND ‘‘human challenge study’’ (all ﬁelds) OR
‘‘experimental study’’ (all ﬁelds) OR ‘‘controlled human infection’’
(all ﬁelds) AND ‘‘randomized controlled trials’’ (all ﬁelds).
There were 520 hits with the use of these search terms. All
520 abstracts were reviewed carefully by the two authors and
judged for suitability for inclusion in the analysis based on the
following inclusion criteria: purposeful infection of volunteers;
randomized design and comparison of a test drug or vaccine versus
a placebo control. Review papers, papers without outcomes, trials
of community-acquired infections (rather than intentional infec-
tions), duplicated data, non-randomized and observational trials,
pathogenesis studies, animal model studies, and studies using
pathogens other than inﬂuenza virus for the challenge were
excluded. Applying these inclusion and exclusion criteria resulted
in 26 papers for inclusion in the analysis (Figure 1).
The following data were extracted systematically from the text,
tables, and/or ﬁgures of the ﬁnal 26 papers by applying a
standardized format: research question; type of study (e.g. vaccine
efﬁcacy/antiviral efﬁcacy); country of study; characteristics of the
challenge virus; reported serious adverse events (SAEs); occur-
rence of acute respiratory illness as deﬁned in each trial;
laboratory-conﬁrmed inﬂuenza infection; main ﬁndings.
The Jadad score was calculated to determine the quality of the
reporting.19 The Jadad score measures the quality of the methods
used and reported in a clinical trial and takes into account ﬁve
parameters: randomization and the method of randomization,
blinding and the method of blinding, and withdrawals or dropouts.
Based on these parameters, a clinical trial could receive a score of
0 to 5, with 5 being optimal.
3. Results
The ﬁnal analysis included 26 eligible articles published
between 1963 and 2014. All of these trials were conducted in
the USA, UK, New Zealand, and Russia. All subjects were healthy
adults aged between 18 and 65 years. All subjects were screened
for serum haemagglutination inhibition (HAI) antibody titres to
assess eligibility for participation in the trials, with 81% of the trials
requiring volunteers to have a haemagglutination inhibition unit
(HAIU) titre of 8 HAIU.
3.1. Jadad score
Each trial was reviewed against each parameter and given a
Jadad score (see Table 1). Of the 26 papers presented in this
systematic review, only one received a score of 5; the median score
was found to be 3.20
3.2. Challenge virus
Three inﬂuenza A subtypes (A/H3N2, A/H1N1, A/H2N2) and/or
inﬂuenza B were the strains of inﬂuenza virus used in the trials
(Table 2). Twenty of the 26 studies were conducted with an
inﬂuenza A virus, three with an inﬂuenza B virus, and three with
Figure 1. Pathway for determining the inclusion of papers in this review. (*Three additional papers by Hayden et al. (1982), Jackson et al. (1963), and Merigan et al. (1973),
which did not appear as a result of the PubMed search with the search terms used, were included for full-text review; this resulted in the inclusion of a total of 26 papers in this
systematic review.15–17 Jackson et al. (1963) and Merigan et al. (1973) were sourced from a review paper by Hayden (2012), and Hayden et al. (1982) was provided by the
author for inclusion.15–18).
S. Balasingam, A. Wilder-Smith / International Journal of Infectious Diseases 49 (2016) 18–2920both inﬂuenza A and B viruses (in different cohorts). The most
common inﬂuenza A virus strain used was A/Texas/39/91 (H1N1)
when an inﬂuenza A strain was used (30% of the studies);
B/Yamagata/16/88 was the most common inﬂuenza B virus strain
when a B strain was used (50% of studies).
The inoculum titre of the challenge virus used in these studies
varied from a dose of 103.9 50% tissue culture infective dose
(TCID50)/ml to 10
7.2 TCID50/ml, whilst Merigan et al. reported using
105.8 50% egg infective dose (EID50).
17 The majority of studies
inoculated volunteers with a total of 500 ml (250 ml per nostril).
Two studies inoculated volunteers with 1 ml in total.21,22 All
26 studies reported inoculating volunteers via the intranasal route,
usually through nasal drops, except for one study where subjects
were inoculated using an intranasal spray.16 Jackson et al. did not
report any details of the challenge virus inoculum except to state
that the volunteers were inoculated with an Asian inﬂuenza A virus
(A/H2N2).15
The challenge virus used in 13 of these papers was speciﬁcally
reported to have been safety tested prior to inoculating volunteers
and produced according to good manufacturing practice (GMP)
standards, either by the National Institute of Health/National
Institute of Allergy and Infectious Diseases (NIH/NIAID) or a
commercial company (Table 2). Three studies reported that the
challenge virus had been passaged in speciﬁc pathogen-free eggs
prior to use only. Although not speciﬁcally stated at all times, all
challenge strains produced by NIH/NIAID were safety tested
(personal communication with Fred Hayden). The remaining
studies did not report speciﬁc information on safety testing for
the challenge virus.
3.3. Procedures performed in the challenge studies
In general, the studies followed similar procedures. Healthy
adults with HAI titres below a deﬁned titre to the challenge virus
were selected. Following informed consent, subjects underwent a
complete physical examination and had blood samples taken for
standard biochemistry and haematology testing and urine/serum
taken for pregnancy testing; subjects were often screened for
chronic blood-borne infections (e.g. hepatitis B virus (HBV),
hepatitis C virus (HCV), and HIV). Depending on the type of study,
volunteers were immunized (single or two sequential doses; in
one study up to 3–4 months prior to challenge), or received
chemoprophylaxis prior to being inoculated. Treatment studies
typically involved the initiation of dosing within 24 h after virus
inoculation, whilst studies on chemoprophylaxis involved initi-
ating the dosing of volunteers 24–72 h prior to virus inoculation.On inoculation with the challenge virus, volunteers were
quarantined for 7 to 10 days. During the quarantine period
volunteers ﬁlled in a daily diary card to record symptoms (e.g.,
sore throat, cough, runny nose, headache, fatigue, earache, etc.).
Volunteers also had their oral temperature taken up to six times
a day, although one trial had axillary temperatures taken.16
All studies except for one that used nasal swabs, reported
nasal washing as a means to determine virus shedding.23 These
were performed the day after challenge, in some cases on a daily
basis, or on alternative days in others until the day of
discharge. Some studies also did nasal washing on subjects the
day before virus challenge. Two studies reported the use of
oseltamivir treatment prior to the release of volunteers from
quarantine with the aim of ceasing virus shedding for public
health reasons.22,23
3.4. Sample size calculations
The sample size used in challenge studies evaluating
prophylactics or therapeutics need to account for the attack rate
of the challenge virus ascertained in a preceding dose-ranging
study. The sample size should be calculated taking into account
the anticipated attack rate in the control group (e.g., from dose-
ranging studies) and the expected effect size of the intervention.
The sample size of volunteers used in all of these challenge
studies was relatively low in comparison to ﬁeld trials: the
maximum number of subjects in the studies reported in this
systematic review was 287 and the lowest 15.24,25 The larger
trials involved enrolling serial cohorts of subjects. The dropout/
withdrawal rates were very low to absent for the total number of
subjects taking part in these trials. Sixteen studies did not report
any dropouts/withdrawals; 10 studies reported dropouts/with-
drawals but these were low.26–28 The largest number of subject
dropouts was reported by Barroso et al., with 20 subjects
withdrawing prior to virus inoculation or drug dosing and two
being withdrawn due to adverse events (AEs) being experienced
with the study drug; still, 288 subjects underwent the challenge
study.25 Some trials excluded data obtained from subjects for a
number of reasons: due to retrospective HAI testing showing high
pre-inoculation HAI titres, lack of documented infection after
virus inoculation, and proven existence of an infection with a
non-challenge virus.20,24,29–33 Some studies also withdrew
subjects based on AEs being experienced with the study
drugs.21,33 Jones et al. also withdrew a subject from the study
from entering quarantine, as the subject was deemed unsuitable
for the challenge study.22
Table 1
Summary of each study (all studies randomized, double-blinded, and with an untreated challenged control group, unless stated otherwise)
First author
and year
Country
of study
Jadad
Score
Purpose Study design Main conclusions
Jackson15 USA 1 Evaluation of adamantine
hydrochloride against inﬂuenza A
infection
Volunteers received adamantine
hydrochloride either 18 h prior to
challenge or 4 h post challenge
Treatment 4 h post challenge resulted
in a 72% reduction in infection in the
<10 HAIU group but only a 10%
reduction in the 20 HAIU group.
Therefore there is no therapeutic effect
with a high antibody level.
Volunteers in the <10 HAIU group
receiving prophylaxis had an infection
rate of 37%, a statistically signiﬁcant
reduction when compared to the
placebo control group.
Adamantine hydrochloride when given
18 h prior to challenge resulted in a 46%
protective efﬁcacy against infection as
determined by a rise in antibody levels
in seronegative individuals.
Beare51 UK 3 To evaluate the efﬁcacy of an
adamantane compound
Volunteers administered either
adamantane capsules or placebo
capsules twice daily on day 2 for 7 days
and challenged on day 4
There was a reduction in clinical
symptoms (20%), virus shedding (30%),
and seroconversion frequency (23%) in
the adamantane treated group when
compared to the placebo group.
Merigan17 UK 2 Evaluation of prophylactic interferon
against B/Hannover/1/70
Subjects administered 800 000 units of
interferon in 16 doses at 4 time-points
(24 h, 5 h, 3 h, and 1 h) prior to
challenge with B/Hannover/1/70
There was no reduction in the
frequency or severity of inﬂuenza
infection in terms of clinical signs,
seroconversion, and virus shedding.
Interferon treatment was found to
delay the onset of infection (as
evidenced by the low symptom scores)
by 2 days when compared to the control
group.
Douglas35 USA 3 Evaluation of a topical interferon
inducer, CP-20.961, against challenge
with A/England/42/72 (H3N2)
Subjects administered CP-20.961 or
placebo on days 1–7, 4 times a day, and
inoculated with the challenge virus on
day 3
No efﬁcacy determined for CP-20.961
Betts32 USA 4 Evaluation of a live attenuated
inﬂuenza virus vaccine (A/Scotland/74
(H3N2)) against challenge with A/
Victoria/3/75 (H3N2)
Subjects administered vaccine or
placebo intranasally and then
challenged 37 days later with
A/Victoria/3/75 (H3N2)
The live attenuated vaccine exhibited
signiﬁcant efﬁcacy against illness
following challenge with A/Victoria/3/
75.
Only 52.4% of vaccine recipients
showed clinical symptoms compared to
85.7% of the placebo recipients.
Hayden16 Russia 1 To evaluate the therapeutic effect of
aerosolized and oral rimantadine
against challenge with A/Khabarovsk
(H1N1)
Subjects inoculated with inﬂuenza
virus and started on either aerosol
treatment (rimantadine 25 mg or
saline, 10 min daily) or oral treatment
(rimantadine 50 mg or placebo, 3 times
daily)
Low doses of aerosolized rimantadine
had a therapeutic effect comparable to
that with the larger dose of oral
rimantadine and both were effective
when compared to the placebo.
Neither drug group showed a peak in
illness score as observed in the placebo
group, and the drug groups showed
reduced mean illness scores of >4.4
when compared to the placebo group.
Clements14 USA 3 Evaluation of a live attenuated, cold-
adapted inﬂuenza vaccine vs. an
inactivated vaccine against A/
Washington/897/80 (H3N2)
Subjects received either 1 dose of
attenuated cold-adapted vaccine
intranasally (3 titres were evaluated in
total) or the inactivated vaccine
intramuscularly and were challenged
5–8 weeks after
The highest dose of the live attenuated
cold-adapted virus vaccination (107.5
TCID50) completely protected subjects
from illness by A/Washington/897/80
and reduced virus shedding by
1000 times compared to the inactivated
vaccinees.
Al-Nakib21 UK 3 Evaluation of an antiviral ICI 130,685
(prophylactic and therapeutic) against
inﬂuenza A A/England/40/83 (H3N2)
Prophylactic study
Study 1: 2 tablets of 200 mg ICI 130,685
or 2 placebo tablets once a day for
7 days; Study 2: 1 tablet of 100 mg ICI
130,685 or 1 placebo tablet a day for
7 days; 3 doses prior to viral inoculation
Therapeutic study
Volunteers exhibiting symptoms for
6–15 h received 200 mg ICI 130,685 or
placebo for 4 days
Prophylactic study
100 mg/day was 72% effective at
reducing illness.
Therapeutic study
200 mg/day, reduction in virus
shedding observed. Signiﬁcant
reductions seen from day 3 only.
Treanor52 USA 3 Evaluation of interferon prophylaxis
against inﬂuenza A, A/California/78
(H1N1)
Subjects were given either IFN-a2 or a
placebo spray 48 h prior to challenge
and then 5 days post challenge (after
the 5th dose); the dosage was 5  106 IU
twice per day
IFN-a2 reduced illness, resulted in
lower mean virus shedding titres and
reduced the duration of virus shedding
(23%).
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Table 1 (Continued )
First author
and year
Country
of study
Jadad
Score
Purpose Study design Main conclusions
Reuman26 USA 3 Evaluation of the efﬁcacy and safety of
low dosage amantadine as prophylaxis
against inﬂuenza A, A/Bethesda/1/85
(H3N2)
Subjects administered placebo,
amantadine 50 mg/day, amantadine
100 mg/day, or amantadine 200 mg/
day for 8 days (3 prior to challenge and
for 5 days post challenge)
200 mg/day was 32% effective at
reducing infection.
100 mg/day was 40% effective at
reducing infection with fewer side
effects than 200 mg/day.
Keital38 USA 2 Evaluation of a cold recombinant
inﬂuenza vaccine virus (CRB 87) against
a homotypic challenge B/Texas/1/84
Following a dose-ranging study, the
highest dose of CRB 87 vaccine was
rechallenged with CRB 87 (issues with
B/Texas/1/84), 3–4 months after the
ﬁrst inoculation with the control group
The CRB 87 vaccine was 54% effective at
reducing the infection rate on
rechallenge with CRB 87.
Fries36 USA 3 Evaluation of the safety,
immunogenicity, and protective
efﬁcacy of a recombinant protein
inﬂuenza A vaccine against A/
Kawasaki/86 (H1N1)
Subjects were vaccinated twice 22 days
apart and challenged along with the
unimmunized control group 58–61
days after the ﬁrst vaccination
The recombinant protein inﬂuenza A
vaccine was 33.3% effective at reducing
clinical illness when compared to the
control.
Hayden33 USA 2 Efﬁcacy of an oral antiviral, LY217896,
for the prevention of experimental
inﬂuenza A virus A/Kawasaki/86
infection and illness
Subjects received either LY217896
(75 mg dose) or placebo once a day for
7 days; subjects were challenged with
A/Kawasaki/86 after the 2nd dose
LY217896 did not reduce the rate of
inﬂuenza infection or the clinical
symptoms of treated subjects.
Youngner37 USA 2 Efﬁcacy of simultaneous
administration of cold-adapted and
wild-type inﬂuenza A virus against
challenge with A/Kawasaki/86
The study consisted of 3 groups, (1)
mixed cold-adapted and wild-type
virus, (2) the cold-adapted virus alone,
and (3) wild-type virus (A/Kawasaki/
86) alone
There was some evidence of reduced
pathogenicity in the mixed virus group
when compared to the wild-type group
alone.
The cold-adapted virus when compared
against the wild-type alone had
reduced illness (14.3% vs. 42.9%) and a
100% reduction in fever.
Hayden29 USA 3 Safety and efﬁcacy of the
neuraminidase inhibitor GG167 in
experimental human inﬂuenza
A/Texas/91 (H1N1)
Four studies; prophylaxis where dosing
(3 groups with intranasal drops,
1 group with a spray) was performed
4 h prior to viral challenge, early
treatment (intranasal drops) where
dosing occurred 26–32 h after
inoculation, or delayed treatment
(intranasal drops) where dosing
occurred 50 h after inoculation; dosing
continued for 4 days in the treatment
study and for 5 days in the prophylaxis
study
Prophylaxis activity:
GG167 as drops was 96% effective at
reducing viral shedding and 82%
effective at reducing infection.
GG167 as a spray was 83% effective at
reducing virus shedding and 60%
effective for reducing infection.
Therapeutic activity:
Early treatment was 84% effective at
reducing fever and 40–65% effective at
reducing clinical symptoms.
Late treatment resulted in a reduction
in virus titre on shedding and a 1-day
reduction in shedding.
Walker34 USA 3 Evaluation of the effects of the
neuraminidase inhibitor zanamivir on
otological manifestations on
experimental inﬂuenza (A/Texas/36/91
and B/Yamagata/88)
Two arms for the inﬂuenza A study;
prophylaxis with drug administration
4 h before challenge virus inoculation
and early treatment starting 1 day after
challenge virus inoculation. Zanamivir
administered as either a spray or drops.
The inﬂuenza B study involved
prophylactic treatment only using
3 doses of zanamivir
Inﬂuenza A/Texas/36/91
Prophylaxis: zanamivir was effective at
reducing infection 13% vs. 73%
(placebo), fever 2% vs. 36% (placebo),
upper respiratory illness 26% vs. 61%
(placebo), and MEP abnormalities 15%
vs. 61% (placebo).
Early treatment: zanamivir was
effective in reducing fever 6% vs. 38%
(placebo), upper respiratory illness 52%
vs. 81% (placebo), and MEP
abnormalities under-pressure 32% vs.
65% (placebo) and over-pressure 6% vs.
27% (placebo).
Inﬂuenza B/Yamagata/88
Zanamivir was effective at reducing
infection and upper respiratory illness
52% vs. 100% (placebo) and MEP
abnormalities 16% vs. 44% (placebo).
Doyle28 USA 4 Evaluation of rimantadine treatment on
clinical manifestations and otological
complications against inﬂuenza A A/
Kawasaki/86
Subjects challenged with virus on day
0 and then treated with either
rimantadine (100 mg) or placebo 48 h
after challenge; dosing occurred at 12-h
intervals for 8 days (5 days in
quarantine and 3 outpatient visits)
Rimantadine signiﬁcantly reduced total
symptoms on days 4 to 6.
Calfee31 USA 4 Evaluation of IV zanamivir in
preventing experimental inﬂuenza A A/
Texas/36/91
Subjects given zanamivir (IV) 4 h before
virus inoculation at a dose of 600 mg;
subjects were dosed over 30 min every
12 h for 5 days
Zanamivir signiﬁcantly reduced fever
14.3% vs. 87.5% (placebo), and reduced
both upper respiratory symptoms and
myalgia by 100%.
Fritz24 USA 2 Evaluation of nasal cytokine and
chemokine responses with zanamivir
on infection with inﬂuenza A A/Texas/
36/91 (H1N1)
Subjects received zanamivir (600 mg)
IV twice a day or placebo starting 4 h
before virus inoculation
Zanamivir signiﬁcantly reduced
infection and illness in the recipients
against inﬂuenza A infection.
Zanamivir also reduced the increase in
cytokines and chemokines.
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Table 1 (Continued )
First author
and year
Country
of study
Jadad
Score
Purpose Study design Main conclusions
Hayden20 USA 5 Evaluation of oseltamivir, an oral
neuraminidase inhibitor against
inﬂuenza A A/Texas/36/91 infection
Two studies
Prophylactic study: oseltamivir
(100 mg, once daily and twice daily)
administered 26 h prior to virus
inoculation; therapeutic study:
oseltamivir at 20 mg, 100 mg, 200 mg
twice daily, 200 mg once daily, or
placebo, all given for 5 days
Prophylaxis (26 h prior to virus
administration) and early treatment
(28 h post virus administration) with
oseltamivir signiﬁcantly reduced
infection and the severity and duration
of clinical symptoms on challenge with
A/Texas/36/91.
Skoner47 USA 2 Evaluation of cytokine mediation of
disease expression in adults challenged
with inﬂuenza A A/Kawasaki/9/86
(H1N1)
Subjects challenged with A/Kawasaki/
9/86; 48 h after virus inoculation,
administered with rimantadine
(100 mg) or placebo, with dosing at
12-h intervals over 8 days
The rimantadine treated group had
lower virus shedding, systemic
symptom scores, and IL-8 secretion
levels.
Hayden30 USA/UK/
New
Zealand
3 Evaluation of oral oseltamivir in adults
experimentally infected with inﬂuenza
B/Yamagata/16/88
Three studies performed; studies A and
B evaluating tolerability and efﬁcacy of
early treatment oseltamivir (75 mg or
150 mg twice daily for 5 days, 24 h after
virus inoculation) and study C
evaluating oseltamivir prophylaxis
(75 mg once or twice daily for 7 days
starting 24 h prior to virus inoculation)
Given as prophylactic, oseltamivir was
effective at reducing infection by 61%
and reduced virus shedding and illness
by 100%.
As treatment, oseltamivir reduced virus
shedding and symptom scores.
Treanor27 USA 4 Evaluation of trivalent, live, cold-
adapted (CAIV-T) and inactivated (TIV)
inﬂuenza vaccines against challenge
with inﬂuenza A (H1N1), A (H3N2), and
B viruses
Subjects underwent vaccination
28 days prior to virus inoculation;
subjects were given (1) CAIV-T by
intranasal spray with IM saline placebo,
(2) TIV IM with intranasal placebo
spray, or (3) IM and intranasal placebos
CAIV-T was just as effective (69%, 93%)
at protecting against inﬂuenza
infection and illness as the TIV (84%,
87%), compared to control (45%, 55%).
CAIV-T was effective in preventing
respiratory illness with either isolation
of inﬂuenza virus from the nasal
washes or at least a 4-fold increase in
HAI antibody after wild-type challenge.
The level of efﬁcacy against this
endpoint of preventing respiratory
illness was slightly higher with CAIV-T
than with TIV (85% compared to 71%)
Barroso25 USA 4 Evaluation of the oral neuraminidase
inhibitor peramivir in experimental
human inﬂuenza (A/Texas/36/91
(H1N1) and B/Yamagata/16/88)
Four studies performed; prophylaxis
(administration 24 h prior to virus
inoculation for 4 days with doses
ranging from 50 to 800 mg/day) and
treatment (administration 24 h after
virus inoculation for 5 days with doses
ranging from 100 to 800 mg/day)
Peramivir demonstrated signiﬁcant
antiviral effects as treatment against
both viruses on a once-daily basis
following inoculation with virus.
There were no signiﬁcant reductions in
any of the parameters tested when
peramivir was used as prophylaxis.
Jones22 UK 4 Evaluation of a trivalent (A/New
Caledonia/20/99, A/Panama/2007/99,
and B/Jiangsu/10/2003) DNA vaccine
against inﬂuenza A A/Panama/2007/99
(H3N2) using a novel approach
Subjects were vaccinated with either
4 mg trivalent DNA vaccine, 2 mg
trivalent DNA vaccine, or an adjuvant
known as DNA encoded
immunostimulator-labile toxin
(DEI-LT) or placebo 56 days prior to
virus inoculation; the vaccine was
administered via the epidermis on
microscopic gold beads
This study shows that a trivalent DNA
vaccine has efﬁcacy against infection
with A/Panama/2007/99.
The group vaccinated with 4 mg
trivalent DNA vaccine when compared
to the placebo exhibited lower rates of
illness (37% vs. 63%) and a lower rate of
laboratory-conﬁrmed inﬂuenza illness
(33.3% vs. 61.5%).
Ramos23 UK 3 Evaluation and safety of treatment with
an anti-M2e monoclonal antibody in
experimental human inﬂuenza
Volunteers were inoculated
intranasally with inﬂuenza A/
Wisconsin/67/2005 (H3N2) and
received 1 dose of the study drug, TCN-
032, or placebo 24 h later
TCN-032 was found to be safe and well-
tolerated.
The number of AEs reported was similar
in the treatment and placebo arms.
The primary efﬁcacy parameter was to
evaluate the proportion of grade 2
inﬂuenza symptoms after challenge
and it was found that 48% of the placebo
group had symptoms of grade 2
compared to 34.5% of the TCN-032
treated group.
It was also determined that the TCN-
032 group had lower total symptom
scores and shortened duration of
symptoms.
HAIU, haemagglutination inhibition unit; TCID, 50% tissue culture infective dose; IFN, interferon; MEP, middle ear pressure; IV, intravenous; IL, interleukin; IM,
intramuscular; HAI, haemagglutination inhibition; AE, adverse event.
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Table 2
Challenge virus details
First author
and year
Challenge virus strain Characterization of
challenge virus
Dose
(TCID50/ml/ EID50)
Intranasal
inoculation
method
Volume (ml)
of virus
given (total)
Source of
challenge
virus
Jackson15 Asian inﬂuenza virus (H2N2) NR NR NR NR NR
Beare51 A/Hong Kong/68 (H3N2) NR 105.0 to 106.5 NR NR NR
Merigan17 B/Hannover/1/70 NR 105.8 EID50 Nasal drops NR Dr A.S. Beare
Douglas35 A/England/42/72 (H3N2) Safety tested NR Nasal drops 500 NR
Betts32 A/Victoria/3/75 (H3N2) Safety tested 106.1 NR NR NR
Hayden16 A/Khabarovsk/77 (H1N1) NR 107.2 NR NR NR
Clements14 A/Washington/897/80
(H3N2) lot E174
Safety tested 106.0 NR NR Children’s Hospital
National Medical
Center of Washington, DC
Al-Nakib21 A/England/40/83 (H3N2) Volunteers infected with
virus passaged in
embryonated eggs; nasal
washes obtained then
passaged in SPF eggs for
further use
104.1 Nasal drops 1000 Central Public
Health Laboratory,
Colindale, UK
Treanor52 A/California/78 (H1N1) Plaque puriﬁed and
passaged in SPF eggs
104.5 Nasal drops 500 NIAID
Reuman26 A/Bethesda/1/85 (H3N2) NR 107.15 NR 500 NIH
Keital38 B/Texas/1/84 clone 6, lot
E-229
NR 103.9,104.9,106.1, 107.1 Nasal drops 500 NIAIDa
Fries36 A/Kawasaki/8/86 (H1N1) Safety tested 107 NR NR NIHa
Hayden33 A/Kawasaki/8/86 (H1N1) Safety tested 107 NR 500 PRI/DynCorp, USA
Youngner37 wt A/Kawasaki/9/86 (H1N1)
(CI 2-1, lot E-262) and a
mixture of the wt A/Kawasaki/
9/86 and cold adapted
A/Kawasaki/86 virus
(CR 125, lot E-271)
NR 107 NR 500 PRI/DynCorp, USA
Hayden29 A/Texas/91 (H1N1) Safety tested 105 Nasal drops 500 NIAIDa
Walker34 A/Texas/36/91 (H1N1) and
B/Yamagata/88
Safety tested 107 NR 500 NIHa
Doyle28 A/Kawasaki/9/86 (H1N1)
lot E-262
Safety tested 107 Nasal drops 500 NIHa
Calfee31 A/Texas/36/91 (H1N1) Safety tested 105 Nasal drops 500 NIAIDa
Fritz24 A/Texas/36/91 (H1N1) Safety tested 105 NR 500 NIAID, NIHa
Hayden20 A/Texas/36/91 (H1N1) Safety tested 106 Nasal drops 500 NIAIDa
Skoner47 A/Kawasaki/9/86 (H1N1) wt,
lot E-262
NR 107 NR 500 NIAID, NIHa
Hayden30 B/Yamagata/16/88 Safety tested 107 Nasal drops 500 NIHa
Treanor27 A/Texas/36/91 (lot E-349)
(H1N1), A/Shangdong/9/93
(H3N2) (lot E-337) B/Panama
/45/90 (lot E-352)
NR 107 Nasal drops 500 DynCorp, USA
Barroso25 A/Texas/36/91 (H1N1) and
B/Yamagata/16/88
Safety tested A/Texas 106
B/Yamagata 107
Nasal drops 500 NIAIDa
Jones22 A/Panama/2007/99 (H3N2) NR 106 NR 1000 NR
Ramos23 A/Wisconsin/67/2005 (H3N2) NR 105.0–5.5 NR NR NR
TCID, 50% tissue culture infective dose; EID, egg infective dose; SPF, speciﬁc pathogen-free; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institute
of Health; wt, wild-type.
a Although not reported, NIH/NIAID will have carried out safety testing on these challenge strains (personal communication with Professor Fred Hayden).
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Such data are beneﬁcial for future challenge studies to narrow
down the inoculum titres required in dose-ranging studies.
3.5. Infection rate and virus shedding
In controls, the challenge virus infection rates (deﬁned either by
isolation of virus or antibody response) varied from 26%15 (note
these volunteers had a pre-challenge HAI titre of 20) to 100%
(Table 3). The virus shedding data reported a rate of 74% for
A/H3N2, 80% for A/H1N1, and 67.1% for B/inﬂuenza. Where peak
nasal virus titres were reported, those for upper respiratory
symptoms (URI) and virus shedding were on day 2 and/or day
3 post virus inoculation for both A strain subtypes and for type B
inﬂuenza. Virus shedding was determined via titration on caninekidney cells in 81% of the studies. Jones et al. and Ramos et al. both
reported using PCR to evaluate virus shedding from the nasal
washes obtained from volunteers, whilst Merigan et al. reported
inoculating embryonated eggs followed by the HAI assay to
evaluate virus shedding.17,22,23
3.6. Clinical illness
Clinical illness rates and virus shedding rates varied from trial
to trial. Where URI symptoms such as runny nose, nasal stufﬁness,
sore throat, and sneezing were reported, the proportion of URI
symptoms for each strain in the untreated challenged individuals
was 54% for A/H3N2, 68% for A/H1N1, and 53% for B/inﬂuenza. The
deﬁnition of fever also varied from >37.7 8C to >38.0 8C across
studies. A low incidence of fever was reported in three studies
Table 3
Infection rate of untreated challenged individuals and documented adverse events
First author
and year
Number of subjects:
untreated and
challenged (total
number challenged)
Infection rate, clinical illness, and laboratory data (%) AEs in relation to the
challenge virus
Illnessa Feverb Laboratory-
conﬁrmed
illnessc
Virus
shedding
Sero-
conversion
(4-fold)
Infection
rated
Jackson15 (21, 20 HAIU;
90, <10 HAIU)
111 total (238)
NR NR NR NR NR 26% 20 HAIU
73% <10 HAIU
NR
Beare51 29 (57) 34 NR NR 66 62 NR NR
Merigan17 11 (22) 73 45 NR 73 80 NR NR
Douglas35 10 (20) 70 30 NR 50 40 50 NR
Betts32 21 (42) 76 24 NR 95 81 100 NR
Hayden16 12 (36) 75 58 NR 58 58 NR None in relation to the virus
Clements14 24 (81) 46 38 (febrile or
systemic/ both)
NR 83 NR 96 NR
Al-Nakib21 40
(prophylactic 200 mg)
33 NR 85 85 78 93 AEs reported, but no details
provided
28
(prophylactic 100 mg)
(227)
50 NR 89 89 75 93
Treanor52 9 (25) 56 NR NR 81 56 NR NR
Reuman26 19 (78) 58 NR NR 95 68 95 Severe headache reported
as a severe AE
Keital38 16 (98) 31c NR NR 100 44c 100 Transient asymptomatic
elevation in serum
transaminase levels in
1 subject resulting in
challenge virus not used
Fries36 16 (31) 80 40 NR 81 94 94 NR
Hayden33 16 (34) 69 6 NR 100 81 NR None in relation to the
challenge virus
Youngner37 14 (27) 43 21 NR 71 100 36 NR
Hayden29 33
prophylactic
61 36 NR 70 70 73 None in relation to the
challenge virus
26e
early treatment
81 38 NR 92 96 NR
26e
delayed treatment
(166)
NR NR NR 92 96 NR
Walker34 33 H1N1
prophylactic
61 36 NR NR NR 73 NR
26e H1N1
treatment
81 38 NR NR NR NR
9 (B)
prophylactic
(185)
100 0 NR NR NR 100
Doyle28 53 (103) 53 0 NR 79 87 92 None in relation to the
challenge virus
Calfee31 8 (16) 100 88 NR 100 100 100 Two severe AEs; 1 severe
‘overall discomfort’ 2 days
after dosing, which
resolved in 3 days; 1 severe
headache that resolved
within 3 h
Fritz24 8 (15) 100 88 NR 100 NR NR NR
Hayden20,g 13
(prophylactic)
33 25 67 50 NR NR None in relation to the
challenge virus
16e
(therapeutic)
(117)
NR 13 81 100 NR 81
Skoner47 38 (72) NR NR NR 84 NR NR NR
Hayden30 13e
treatment
69 0 100 85 77 80 None in relation to the
challenge virus
29e
treatment
24 3 100 90 76 77
19
prophylactic
(235)
21 10 NR 74 63 84
Treanor27 12 (H1N1) NR NR 50 50 50 58 None in relation to the
challenge virus8 (H3N2) NR NR 50 25 50 50
11 (B)
(103)
NR NR 36 18 36 36
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First author
and year
Number of subjects:
untreated and
challenged (total
number challenged)
Infection rate, clinical illness, and laboratory data (%) AEs in relation to the
challenge virus
Illnessa Feverb Laboratory-
conﬁrmed
illnessc
Virus
shedding
Sero-
conversion
(4-fold)
Infection
rated
Barroso25 37e (H1N1)
treatment
NR 24 (H1N1) 94 (H1N1) 94 (H1N1) NR 94 (H1N1) One serious AE was
reported during the study
when a subject developed a
dilated cardiomyopathy
following challenge. At the
last follow-up visit 5 years
post study, the serious AE
had resolved
19e (B)
treatment
NR 0 (B) 42 (B) 42 (B) NR 95
19 (H1N1)
prophylactic
NR NR NR 58 NR 74
20 (B)
prophylactic
(287)
NR NR NR 55 NR 90
Jones22 27 (86) 63 33 61.5 NR NR NR None in relation to the
challenge virus
Ramos23 31 (61) NR 61 NR NR 92 NR 93% had mild or moderate
AEs such as abnormal
spirometry results,
epistaxis, and increased
levels of ALT, CRP, and AST
AEs, adverse events; HAIU, haemagglutination inhibition unit; NR, not reported; ALT, alanine aminotransferase; CRP, C-reactive protein; AST, aspartate aminotransferase.
a Deﬁnition of illness varied for each trial.
b Fever (>37.7 to >38.0 8C), or symptoms after virus inoculation (exact deﬁnition varied by trial).
c Subjects with respiratory illness and laboratory evidence of wild-type virus infection.
d Respiratory illness with positive viral culture and/or a 4-fold increase in HAI titre.
e Only infected subjects treated with test antiviral.
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with just 4% of the placebo group demonstrating fever.25,30,34
Of studies with the A/H3N2 subtype, ﬁve reported low numbers
in the control group showing fever.14,22,23,32,35 With the A/H1N1
subtype, 10 studies reported fever in 6% to 88% of the
subjects.16,20,24,25,29,31,33,34,36,37
3.7. Reporting of SAEs related to the challenge virus in the placebo
group
Of 14 trials (11 were antiviral studies), eight stated that there
were no AEs reported in the placebo group in relation to the
challenge virus and two documented AEs that included a severe
headache and overall discomfort. The remaining reported moder-
ate AEs. Table 3 documents the AEs described for each trial in
relation to the challenge virus itself. Twelve of the 26 trials (the
majority were vaccine studies) did not report whether AEs
occurred.
Of the studies that did state AEs, one reported a subject having
an increased serum transaminase level upon challenge with B/
Texas/1/84 in the dose-ranging study.38 As a result of this AE, the
challenge virus in the study was not used to challenge the
vaccinated group of volunteers; the volunteers were instead re-
challenged with the cold-adapted reassortant virus, CR inﬂuenza
B/Texas/1/84.
One study documented a SAE in which a male subject with no
history of cardiac problems developed a dilated cardiomyopathy
following a prophylactic study with the neuraminidase inhibi-
tor, peramivir, after challenge with inﬂuenza B/Yamagata/88
virus.25 This SAE was reported to the US Food and Drug
Administration (FDA). The dilated cardiomyopathy resolved
with angiotensin-converting enzyme inhibitor treatment. The
subject was followed up for 5 years after the study and remained
clinically well.25 The cause of the dilated cardiomyopathy was
not ascertained but deemed unlikely to be due to the study drug
and also deemed unlikely due to be due to the challenge
virus.25,394. Discussion
Twenty-six RCTs published between 1963 and 2014 were
identiﬁed, with 19 studies being performed in the USA, ﬁve in the
UK, and one in Russia; one study was multi-centre, with subjects
recruited in the USA, UK, and New Zealand. These studies involved
2462 subjects in total undergoing challenge. About two-thirds of
these trials were conducted to evaluate different inﬂuenza
antivirals and one-third to evaluate the efﬁcacy of a vaccine
against inﬂuenza. Fewer studies were identiﬁed compared to a
previous systematic review on inﬂuenza challenge studies by
Carrat et al., as only RCTs were included in the present review.40
However, a higher number of subjects who had undergone
challenge studies was identiﬁed in the present review (n = 2462)
compared to the review by Carrat et al. (n = 1280), indicating that
since the period of the previous review (2008), many more trials
using the CHI study approach have been conducted.40 More than
2000 subjects having undergone challenge studies is a sizable
population to assess safety issues and the value of such challenge
studies. Given the ethical issues of intentionally infecting healthy
volunteers, it is important to periodically review and revisit the
value and safety of challenge studies.
The present ﬁndings on the clinical symptoms reported by
inoculated subjects and virus recovery were compared to the data
presented by Carrat et al.40 These ﬁndings are consistent with
those reported by Carrat et al. showing that the titre of inﬂuenza
virus peaked on day 2 in the nasal washing of infected subjects
(placebo/untreated groups), although in one study the peak was on
day 3.35,40 The peak in symptom score followed a day after the peak
in virus recovery on day 3. In the present review, it was found that
the incidence of fever was not documented in all of the papers. The
incidence of fever in the A/H3N2 challenge studies ranged from
24% to 61% in the control groups; in the A/H1N1 challenge studies,
this ranged from 0 to 88% and in the B virus challenge study from
0 to 45%.17,25,30 There is agreement with the statement by Carrat
et al. that the incidence of fever with inﬂuenza A is more common
and frequent when compared to inﬂuenza B.40 In terms of infection
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variation was found in infection rates, from 26% to 100%. One
hundred percent infection rates were achieved in the placebo
group with each strain of inﬂuenza virus H3N2, A/H1N1, and
B.31,32,34,38 In general, the clinical symptoms observed in the
present review were mostly conﬁned to the upper respiratory tract
and were less severe than would be observed in a naturally
acquired inﬂuenza infection.30 Also in agreement with Carrat et al.,
it was found that the majority of studies used A/H1N1 inﬂuenza
virus strains (45%) rather than A/H3N2 (32%) inﬂuenza strains.40
The variation in infection rates is likely due to studies using
different inﬂuenza strains and doses, different challenge lots,
varying handling and monitoring procedures, and different
assaying methods, as well as the quality of the assays used –
both the screening assays and assays such as the titration assay for
determining the inoculum titre. In addition there are other
immune parameters, for example pre-existing inﬂuenza-speciﬁc
CD4 T-cell levels, which may contribute to protection against
inﬂuenza infection and are not part of the screening process.41
As the challenged but untreated control groups had substantial
infection rates and often also showed clinical symptoms and signs
of mild disease, CHI studies with inﬂuenza virus provide a good
platform for studying prophylactic and therapeutic measures for
inﬂuenza. The ﬁrst pivotal study that showed the usefulness of the
challenge platform in evaluating antiviral efﬁcacy was performed
by Jackson et al. in 1963.15 That study demonstrated the antiviral
effect of amantadine for the ﬁrst time using experimental infection
in volunteers with an attenuated inﬂuenza A virus strain. Jackson
et al. determined that by administering amantadine, the clinical
symptoms and viral shedding were reduced.15 They also showed
that there was a 46% protective efﬁcacy against infection, as
determined by a rise in antibody levels in seronegative individua-
ls.15 These ﬁndings led to amantadine being studied in further CHI
studies and ﬁeld studies, which supported the data demonstrated
by Jackson et al. in their challenge studies.6,15,42–45 Smorodintseff
et al. showed that amantadine was able to prevent infection in 51%
of infected volunteers when given prophylactically and that those
who did develop inﬂuenza had a mild form.6
When tested using the human challenge platform, rimantadine,
an analogue of amantadine, was found to reduce the proportion
and severity of Asian inﬂuenza.46 Subsequently, both amantadine
and rimantadine were approved for use as treatment against
inﬂuenza by the FDA (1966 and 1994, respectively). Whilst efﬁcacy
was conﬁrmed in follow-up CHI studies utilizing drug-susceptible
virus,26,28,47 there is now widespread resistance among circulating
seasonal inﬂuenza A strains, such that neither is recommended for
routine use anymore.48
Based in part on the data generated by challenge studies over
the past decades, several other antivirals, such as zanamivir,
oseltamivir, and peramivir, progressed into further clinical testing,
which ultimately resulted in FDA approvals.16,20,24,25,29–31,34
Oseltamivir has become the drug of choice in a potential pandemic
situation and has been stockpiled by countries such as the UK and
the USA in amounts costing 0.5 billion USD and 1.5 billion USD,
respectively.49 Resistance to antivirals is increasingly a problem.50
Gubareva et al.,50 in a follow on study from a study by Hayden
et al.,20 used the nasal wash samples from the last day of shedding
from all infected individuals (treated with oseltamivir and
placebo) to determine the frequency of resistance to oseltamivir
in challenged subjects with increasing concentrations of oselta-
mivir due to mutations arising in the N-acetylneuraminic acid
receptor binding site.20,50 The study found an incidence of 4%
neuraminidase resistance as determined by the neuraminidase
inhibition assay.
Five other antiviral trials evaluated four additional antivirals: ICI
130,685 (a cyclo-nonane similar to amantadine), an adamantanecompound, interferon (IFN) a2, and a monoclonal antibody
(TCN-032). ICI 130,685 was tested for prophylaxis and treat-
ment against inﬂuenza A/England/40/83 (H3N2), the adaman-
tane compound was tested for prophylactic activity only against
A/Hong Kong/68 (H3N2), IFN was tested for prophylactic
activity against A/California/78 and B/Hannover/1/70, and
TCN-032 was evaluated for its therapeutic activity against
A/Wisconsin/67/2005.17,21,23,51,52 These showed variable efﬁ-
cacy in reducing viral replication and symptoms of inﬂuenza-
like illness. No evidence could be found that two of these
compounds (the ICI 130,685 antiviral and the adamantane
compound) were developed further after these papers
were published. Treanor et al. demonstrated that IFN-a2
reduced clinical symptoms and virus shedding in volunteers
challenged with inﬂuenza A/California/78 (A/H1N1).52 Merigan
et al. found that prophylaxis with IFN conferred no protection
against inﬂuenza B/Hannover/1/80 infection.17 Contrasting
data for the efﬁcacy of IFN against inﬂuenza has, however,
been found in ﬁeld studies where IFN-a2 was found to have no
clinical beneﬁt in those self-administering.18,53 The antiviral
TCN-032 was found to reduce the proportion of grade 2
inﬂuenza symptoms to 34.5% in the treated group compared to
48% in the placebo control group.23
Of the RCTs investigating the efﬁcacy of vaccines, four vaccines
showed efﬁcacy: a live attenuated vaccine, a recombinant or
recombinant protein vaccine, and a DNA vaccine.14,22,32,36–38 These
RCTs reported efﬁcacy against challenge with inﬂuenza virus
either as efﬁcacy on reducing the incidence of infection or reducing
the severity of clinical symptoms (Table 1). The live attenuated
vaccine tested by Clements et al. was subsequently approved by
the FDA.14
Three of the RCTs showed that the test antivirals or vaccine
were ineffective at reducing laboratory-conﬁrmed infection or
clinical symptoms when compared to the control or comparator
control, and hence these antivirals were not brought forward for
further development, thus saving resources and time.27,33,35 A
good example of this is the oral antiviral LY217896 tested for its
efﬁcacy in volunteers challenged with A/Kawasaki/86 (A/H1N1).
This trial showed no difference in clinical symptoms or virus
shedding between the LY217896 (1,3,4-thiadiazol-2-ylcyanamide)
treated group and the placebo group, demonstrating it to be an
ineffective antiviral against inﬂuenza.33
This review also provided information on the strain and
inoculum dose of the challenge virus and the attack rates these
challenge viruses achieved in healthy volunteers. This information
is important for investigators designing new human challenge
studies. Currently, the regulatory requirements for the virus
inoculum, although different in different countries, require that
the inﬂuenza virus inoculum be manufactured under GMP.3 This
can be a costly and time-consuming procedure; however, it
ensures that the virus inoculum is sterile, pure, and potent and
elicits the expected symptoms (FDA, 21 CFR 600.3 sections (p), (r),
(s)).54
The priority of any clinical trial is the safety of the subjects and
study personnel involved. In challenge studies, this involves
another layer of safety procedures relative to clinical trials of
inﬂuenza-infected outpatients in addition to ensuring that GMP
inoculum is used: the isolation of inoculated subjects is required,
along with appropriate infection control procedures, vaccination of
staff (where appropriate), and the use of personal protective
equipment.18 Human challenge studies have come under scrutiny
for ethical reasons and this has been the subject of a number of
reviews.55–58 The two regulatory bodies (European Medicines
Agency and the FDA) of the two countries where the majority of
human challenge studies are currently performed (USA and UK)
have the same stance as Lynch.57 Their conclusion is that
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relevant difference’’ and so there should not be, in principle, an
objection to human challenge studies. Lynch stated that the risks to
the safety of participants in these studies should not be more than
is acceptable in other forms of research.57 Ultimately inﬂuenza
challenge studies have a good safety record, as found in the present
review, due to the strict inclusion/exclusion criteria of subjects
enrolled, the use of an attenuated inﬂuenza virus challenge strain
with lower pathogenicity than a naturally circulating strain, and
strict regulatory and ethical guidelines in place.55
This review found that while the majority of studies did report
some mild AEs, no medical emergencies or AEs surfaced that
required urgent medical intervention by emergency services.
Furthermore, all AEs were transient. Foremost, no fatalities
related to any inﬂuenza virus challenge studies have ever been
reported. Only one SAE was reported in the 2462 subjects
challenged in these studies (0.04%); this one subject in the USA
developed a dilated cardiomyopathy following infection with an
inﬂuenza B challenge virus.25 Although myocarditis after natural
inﬂuenza B infection is recognized rarely, the cause in this case
was thought unlikely to be due to the challenge virus.59 This
incident did result in human challenge studies being discontinued
in the USA for a number of years until they were restarted with the
dose-ranging study for GMP inﬂuenza A (H1N1)pdm09 by Memoli
et al. in 2015.60
Various shortcomings were found in the reporting of the trials,
as evidenced by an overall low Jadad score. Few studies reported
the methods of randomization, methods of blinding, or reasons for
withdrawal/loss-to-follow-up. It is agreed with Kalil et al. that the
reporting of the study design or set-up of CHI studies is not
consistent or comprehensive enough for future researchers to be
able to replicate the study conditions.61 As many as 48% of the trials
in this review did not document whether and how AEs were
recorded. Only two studies outlined the administration of
oseltamivir to all challenged subjects prior to their subsequent
release from quarantine to prevent the spread of virus to the
community.22,23 Kalil et al. reviewed 181 papers on human
challenge studies and found that only 41% reported the source of
the challenge agent.61 In contrast, in the present review it was
found that 73% reported the source of the inﬂuenza virus inoculum.
The ﬁndings of this systematic review underline the need for better
reporting of human challenge studies and a set of guidelines
speciﬁcally tailored for human challenge studies to ensure
consistency.
Human challenge studies have signiﬁcant limitations. One of
the main limitations is the recruitment of volunteers who have
variable immunity to the inﬂuenza strains utilized. While subjects
are usually selected on the basis of sero-susceptibility with low or
non-detectable antibodies to the challenge organism, speciﬁc pre-
existing cellular immune responses can also affect outcomes in
experimentally inoculated subjects.41 Another is that the patho-
genesis of illness differs from natural inﬂuenza, including key sites
of viral replication, such that the routes of drug delivery cannot be
extrapolated to ﬁeld conditions. For example, intranasal recom-
binant IFN or zanamivir were protective in experimentally
infected subjects but failed to prevent inﬂuenza illness and
infection under ﬁeld conditions.29,31,52,53,62 In contrast, orally
inhaled zanamivir was shown to be an effective prophylactic and
therapeutic agent in naturally occurring inﬂuenza and was
approved for these indications.63,64 Hence, challenge studies
cannot replace efﬁcacy trials.
In summary, these ﬁndings highlight the importance of the CHI
model to down-select potentially effective inﬂuenza vaccines and
antivirals in a timely and cost-effective manner, with small sample
sizes.24 This systematic review also conﬁrms that the incidence of
SAEs in relation to the challenge virus is extremely low. Challengestudies can be safe, ethical, extremely informative, and an efﬁcient
use of resources during the clinical development of vaccines or
therapeutics, but they cannot replace phase 3 trials.
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